News und Analysen
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Form 8.3 - The Vanguard Group, Inc.: Allergan plc](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Form 8.3 - The Vanguard Group, Inc.: Allergan plc](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Form 8.3 - The Vanguard Group, Inc.: Allergan plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--30a4f87e2f6442a34d491960296cefece4f65ecc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/carl_zeiss_meditec_logogif.png?locale=de)
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
![DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--30a4f87e2f6442a34d491960296cefece4f65ecc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/carl_zeiss_meditec_logogif.png?locale=de)
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
![DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--30a4f87e2f6442a34d491960296cefece4f65ecc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/carl_zeiss_meditec_logogif.png?locale=de)
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
![DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--30a4f87e2f6442a34d491960296cefece4f65ecc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/carl_zeiss_meditec_logogif.png?locale=de)
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
![DGAP-News: EVOTEC, INTEGRA HOLDINGS UND YISSUM STARTEN LAB555, UM FRÜHE WIRKSTOFFENTWICKLUNG ZU BESCHLEUNIGEN: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=de)
DGAP-News: EVOTEC, INTEGRA HOLDINGS UND YISSUM STARTEN LAB555, UM FRÜHE WIRKSTOFFENTWICKLUNG ZU BESCHLEUNIGEN
DGAP-News: EVOTEC, INTEGRA HOLDINGS UND YISSUM STARTEN LAB555, UM FRÜHE WIRKSTOFFENTWICKLUNG ZU BESCHLEUNIGEN
![DGAP-News: EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=de)
DGAP-News: EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT
DGAP-News: EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT
![Form 8.3 - The Vanguard Group, Inc.: Allergan plc](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
DGAP-News: Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019
DGAP-News: Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019
DGAP-News: Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019
DGAP-News: Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019
DGAP-News: Telefonkonferenz der MorphoSys AG am 30. Oktober 2019 zu den Ergebnissen des dritten Quartals 2019
DGAP-News: Telefonkonferenz der MorphoSys AG am 30. Oktober 2019 zu den Ergebnissen des dritten Quartals 2019
DGAP-News: Telefonkonferenz der MorphoSys AG am 30. Oktober 2019 zu den Ergebnissen des dritten Quartals 2019
DGAP-News: Telefonkonferenz der MorphoSys AG am 30. Oktober 2019 zu den Ergebnissen des dritten Quartals 2019
![Form 8.3 - The Vanguard Group, Inc.: Allergan plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Form 8.3 - The Vanguard Group, Inc.: Allergan plc](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Form 8.3 - The Vanguard Group, Inc.: Allergan plc](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc